Tissue‐resident CD8+/CD103+/CD39+ T cells are suggested to be tumor‐specific in other contexts, which we support in finding that these secrete IFN‐γ upon stimulation with Nivolumab [6, 7]. Here, ENTPD1 is linked to neoplasm.